Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
The emergence of SARS-CoV-2 variants raised questions regarding the durability of immune responses after homologous or heterologous boosters after Ad26.COV2.S-priming. We found that SARS-CoV-2-specific binding antibodies, neutralizing antibodies, and T cells are detectable 5 months after boosting, although waning of antibodies and limited cross-reactivity with Omicron BA.1 was observed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 76(2023), 3 vom: 08. Feb., Seite e533-e536 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sablerolles, Roos S G [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Ad26.COV2.S |
|---|
| Anmerkungen: |
Date Completed 10.02.2023 Date Revised 05.04.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciac495 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342445359 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342445359 | ||
| 003 | DE-627 | ||
| 005 | 20231226014130.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciac495 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1141.xml |
| 035 | |a (DE-627)NLM342445359 | ||
| 035 | |a (NLM)35723273 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sablerolles, Roos S G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.02.2023 | ||
| 500 | |a Date Revised 05.04.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
| 520 | |a The emergence of SARS-CoV-2 variants raised questions regarding the durability of immune responses after homologous or heterologous boosters after Ad26.COV2.S-priming. We found that SARS-CoV-2-specific binding antibodies, neutralizing antibodies, and T cells are detectable 5 months after boosting, although waning of antibodies and limited cross-reactivity with Omicron BA.1 was observed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Ad26.COV2.S | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a waning immunity | |
| 650 | 7 | |a Ad26COVS1 |2 NLM | |
| 650 | 7 | |a JT2NS6183B |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Rietdijk, Wim J R |e verfasserin |4 aut | |
| 700 | 1 | |a Goorhuis, Abraham |e verfasserin |4 aut | |
| 700 | 1 | |a Postma, Douwe F |e verfasserin |4 aut | |
| 700 | 1 | |a Visser, Leo G |e verfasserin |4 aut | |
| 700 | 1 | |a Schmitz, Katharina S |e verfasserin |4 aut | |
| 700 | 1 | |a Geers, Daryl |e verfasserin |4 aut | |
| 700 | 1 | |a Bogers, Susanne |e verfasserin |4 aut | |
| 700 | 1 | |a van Haren, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Koopmans, Marion P G |e verfasserin |4 aut | |
| 700 | 1 | |a Dalm, Virgil A S H |e verfasserin |4 aut | |
| 700 | 1 | |a Kootstra, Neeltje A |e verfasserin |4 aut | |
| 700 | 1 | |a Huckriede, Anke L W |e verfasserin |4 aut | |
| 700 | 1 | |a Akkerman, Renate |e verfasserin |4 aut | |
| 700 | 1 | |a Beukema, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Lafeber, Melvin |e verfasserin |4 aut | |
| 700 | 1 | |a van Baarle, Debbie |e verfasserin |4 aut | |
| 700 | 1 | |a de Vries, Rory D |e verfasserin |4 aut | |
| 700 | 1 | |a van der Kuy, P Hugo M |e verfasserin |4 aut | |
| 700 | 1 | |a GeurtsvanKessel, Corine H |e verfasserin |4 aut | |
| 700 | 0 | |a SWITCH Research Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 76(2023), 3 vom: 08. Feb., Seite e533-e536 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2023 |g number:3 |g day:08 |g month:02 |g pages:e533-e536 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciac495 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 76 |j 2023 |e 3 |b 08 |c 02 |h e533-e536 | ||